SecBot SecBot
8-K ·Filed Apr 13, 2026

IDYA

IDEAYA Biosciences, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001193125-26-151893
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The strong PFS and ORR data support potential accelerated approval; traders should monitor for NDA submission in H2 2026 and upcoming data presentation at a major medical conference. This could be a catalyst for significant upside given the lack of effective treatments in metastatic uveal melanoma.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$32.82
T+0 close · Apr 13, 2026 · via day close
Latest settled
+15.66%
T+60 · $37.96
Vs SPY
+6.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $32.82entry
  2. T+1 · 7mo ago −1.43%α −2.64% · $32.35
  3. T+5 · 7mo ago +2.38%α −0.92% · $33.60
  4. T+20 · 6mo ago −14.29%α −22.02% · $28.13
  5. T+60 · 4mo ago +15.66%α +6.74% · $37.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences announced positive Phase 2/3 clinical trial results for darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma, showing a 58% reduction in risk of progression and significantly improved median progression-free survival (6.9 vs 3.1 months). The company plans to submit a New Drug Application (NDA) in the second half of 2026.

Key Facts

  • Darovasertib combination met primary endpoint of statistically significant improvement in median PFS (6.9 months vs 3.1 months) with hazard ratio of 0.42 (p < 0.0001)
  • ORR was 37.1% in the darovasertib arm vs 5.8% in the investigator choice therapy arm (p < 0.0001)
  • 5 complete responses observed in darovasertib arm, none in control arm
  • Median DOR was 6.8 months in the darovasertib arm
  • OS data not mature but early trend favoring darovasertib combination
  • Safety profile manageable with Grade 3+ adverse events including diarrhea, syncope, and hypotension
  • NDA submission targeted for second half of 2026

Financial Impact

Potential blockbuster approval in a high-unmet-need orphan indication with no current standard of care; market opportunity estimated at $500M+ annual peak sales

revenuevaluationdilution

Risk Factors

  • OS data not mature, creating uncertainty about overall survival benefit
  • FDA may require confirmatory trial post-approval
  • Competition from other targeted therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-151893
Document: 0001193125-26-151893-index-headers.html0001193125-26-151893
Document: 0001193125-26-151893-index.html0001193125-26-151893
Document: 0001193125-26-151893.txt0001193125-26-151893

Track record

13 reports on IDYA

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.76% at T+20 after the Oct 6, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 9h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026